lyp 1

LyP-1 is a cyclic peptide comprised of 9 amino acids, designed to target and bind selectively to p32 receptors that are overexpressed in a range of tumor-associated cells.

LyP-1 acetate 是一种肿瘤定位肽，可特异性结合在各种肿瘤相关细胞中过表达的 p32 受体。

LyP-1 TFA是一种环肽，由9个氨基酸组成，特异性地与多种肿瘤相关细胞中的p32 receptor蛋白结合，起到定位肿瘤的作用。

LYP-IN-1 is a powerful LYP inhibitor that demonstrates high potency, selectivity, and specificity, with a Ki of 110 nM and an IC 50 of 0.259 μM. Beyond its primary target, LYP-IN-1 also exhibits selectivity towards a wide range of PTPs, including SHP1 (IC 50 = 5 μM) and SHP2 (IC 50 = 2.5 μM). Additionally, LYP-IN-1 demonstrates remarkable efficacy in T- and mast cells, making it a valuable tool for investigating autoimmune disorders.

tLyP-1 peptide 是一种NRP-1靶向肽，IC50为 4 μM，其氨基酸序列为 CGNKRTR。该肽通过与NRP-1的特异性结合，能够靶向肿瘤细胞。

LTV-1 has the potential for autoimmunity treatment. LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM.

p32 inhibitor M36 is an inhibitor of p32 mitochondrial protein. It binds directly to p32 and inhibits the p32 association with LyP-1.

1-Arachidoyl-sn-glycero-3-phosphocholine is a lysophospholipid (LyP).

LYP-IN-3（compound D34）作为一种淋巴酪氨酸磷酸酶（LYP）的选择性抑制剂（Ki=0.93 μM），通过调节T细胞受体（TCR）信号通路发挥在肿瘤进展中的作用。它能够激活T细胞，抑制M2型巨噬细胞的极化，并上调PD-1 PD-L1表达，适合与PD-1 PD-L1抑制剂联合使用，为癌症免疫治疗提供进一步的疗效潜力。

LYP-IN-4（compound D14）是一种针对淋巴酪氨酸磷酸酶（LYP）的可逆且特异性抑制剂，具有Ki值1.34 μM和IC50值3.52 μM。该化合物通过抑制LYP来调控TCR信号传递，并上调PD-1 PD-L1的表达，以此增强抗肿瘤免疫反应。此外，LYP-IN-4能够激活T细胞、抑制M2型巨噬细胞的极化，并在MC38同基因小鼠模型中抑制肿瘤生长。